142 related articles for article (PubMed ID: 36738816)
1. DNA methylation of ITGB2 contributes to allopurinol hypersensitivity.
Liu Y; Wang CW; Chen CB; Yu KH; Wu YJ; Choon SE; Chang WC; Yang F; Luo XQ; Chung WH; Zhao M; Lu QJ
Clin Immunol; 2023 Mar; 248():109250. PubMed ID: 36738816
[TBL] [Abstract][Full Text] [Related]
2. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
3. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong.
Chiu ML; Hu M; Ng MH; Yeung CK; Chan JC; Chang MM; Cheng SH; Li L; Tomlinson B
Br J Dermatol; 2012 Jul; 167(1):44-9. PubMed ID: 22348415
[TBL] [Abstract][Full Text] [Related]
4. The Presence of HLA-B75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers.
Shim JS; Yun J; Kim MY; Chung SJ; Oh JH; Kang DY; Jung JW; Cho SH; Kang HR
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1261-1270. PubMed ID: 30529060
[TBL] [Abstract][Full Text] [Related]
5. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
[TBL] [Abstract][Full Text] [Related]
6. Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
van Nguyen D; Chu HC; Vidal C; Fulton RB; Nguyen NN; Quynh Do NT; Tran TL; Nguyen TN; Thu Nguyen HT; Chu HH; Thanh Thuc HT; Minh Le HT; van Nunen S; Anderson J; Fernando SL
Pharmacogenomics; 2021 Jan; 22(1):1-12. PubMed ID: 33356553
[No Abstract] [Full Text] [Related]
7. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
8. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
Yu KH; Yu CY; Fang YF
Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
[TBL] [Abstract][Full Text] [Related]
10. HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.
Park HJ; Kim YJ; Kim DH; Kim J; Park KH; Park JW; Lee JH
Yonsei Med J; 2016 Jan; 57(1):118-26. PubMed ID: 26632391
[TBL] [Abstract][Full Text] [Related]
11.
Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
[TBL] [Abstract][Full Text] [Related]
13. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians.
Wang CW; Tassaneeyakul W; Chen CB; Chen WT; Teng YC; Huang CY; Sukasem C; Lu CW; Lee YS; Choon SE; Nakkam N; Hui RC; Huang YH; Chang YC; Lin YY; Chang CJ; Chiu TM; Chantratita W; Konyoung P; Lee CN; Klaewsongkram J; Rerkpattanapipat T; Amornpinyo W; Saksit N; Rerknimitr P; Huang YH; Lin SH; Hsu CK; Chan CC; Lin YJ; Hung SI; Chung WH;
J Allergy Clin Immunol; 2021 Apr; 147(4):1402-1412. PubMed ID: 32791162
[TBL] [Abstract][Full Text] [Related]
14. Comparison between the
Saksit N; Nakkam N; Konyoung P; Khunarkornsiri U; Tassaneeyakul W; Chumworathayi P; Kanjanawart S; Sukasem C; Sangviroon A; Pattanacheewapull O; Tassaneeyakul W
J Immunol Res; 2017; 2017():2738784. PubMed ID: 29392141
[TBL] [Abstract][Full Text] [Related]
15. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.
Cao ZH; Wei ZY; Zhu QY; Zhang JY; Yang L; Qin SY; Shao LY; Zhang YT; Xuan JK; Li QL; Xu JH; Xu F; Ma L; Huang HY; Xing QH; Luo XQ
Pharmacogenomics; 2012 Jul; 13(10):1193-201. PubMed ID: 22909208
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the HLA-B
Park HW; Kim DK; Kim SH; Kim S; Chae DW; Yang MS; Oh YK; Lee JP; Jung JW; Shin J; Hwang JH; Kang MG; Kim SM; Kwon SK; Kim HY; Kim MH; Kim SJ; Ryu DR; Cho YJ; Jee YK; Kim SM; Lee EK; Kim JY; Cho HS; Jeong YY; Kim SH; Jun JB; Park JS; Kim GH; Kim S; Jung HY; Lee JM
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1271-1276. PubMed ID: 30580048
[TBL] [Abstract][Full Text] [Related]
17. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
[TBL] [Abstract][Full Text] [Related]
19. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI
Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
[TBL] [Abstract][Full Text] [Related]
20. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
